An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real‐world practice setting: A report from the Fenfluramine European Early Access Program

To examine the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) in three age groups: <6, 6‐17, and ≥18 years old, treated in a real‐world setting.

• Publication year

  2022

• Venue

  Epilepsia Open

• Publication date

  2022-07-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/epi4.12624PMID 35801621PMCID 9712464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real‐world practice setting: A report from the Fenfluramine European Early Access Program

  2022cited by this paper
• Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.

  2021cited by this paper
• Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome.

  2021cited by this paper
• Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany

  2021cited by this paper
• Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study

  2020cited by this paper
• Fenfluramine HCl (Fintepla®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study

  2020cited by this paper
• Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real‐world study

  2020cited by this paper
• Fenfluramine acts as a positive modulator of sigma-1 receptors.

  2020cited by this paper
• Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens

  2019cited by this paper
• Seizure Management and Prescription Patterns of Anticonvulsants in Dravet Syndrome: A Multicenter Cohort Study from Germany and Review of Literature

  2019cited by this paper
• Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.

  2019cited by this paper
• Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey

  2018cited by this paper
• Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population

  2017cited by this paper
• Mortality in Dravet syndrome: A review.

  2016cited by this paper
• Mortality in Dravet syndrome.

  2016cited by this paper
• The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome.

  2015cited by this paper
• Incidence of Dravet Syndrome in a US Population

  2015cited by this paper
• Incidence of Dravet Syndrome in a US Population

  2015cited by this paper
• The core Dravet syndrome phenotype

  2011cited by this paper
• Cognitive side effects of anti-epileptic drugs. The relevance in childhood epilepsy.

  2006cited by this paper

• Proceedings from ERN EpiCARE "BEYOND SEIZURES" meeting, Aalesund, Norway, May the 27th. Advancing holistic care for rare and complex epilepsies in adults.

  2026cites this paper
• Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies.

  2026cites this paper
• Advances in the Treatment of Refractory Epilepsy

  2025cites this paper
• Consider cenobamate and fenfluramine for drug-resistant epilepsy, with development of promising new pharmacotherapies in the pipeline

  2025cites this paper
• α-Asaronol, a Low-Toxicity α-Asarone Metabolite, Suppresses Seizures in Zebrafish Dravet Syndrome via Positive Modulation of GABAA Receptors and LDH Inhibition.

  2025cites this paper
• Dravet syndrome therapeutics: where are we, what works, and what’s next?

  2025cites this paper
• Developmental and epileptic encephalopathies: From current care to future perspectives - insights from epilepsy centres in Lombardy, Italy.

  2025cites this paper
• Monogenic Epilepsies in Adult Epilepsy Clinics and Gene-Driven Approaches to Treatment

  2025cites this paper
• Expert-Agreed Practical Recommendations on the Use of Fenfluramine in Developmental and Epileptic Encephalopathies Based on Clinical Experience and Literature Review

  2025cites this paper
• A Postmarketing Pharmacovigilance Study of Fenfluramine: Adverse Event Data Mining and Analysis Based on the US Food and Drug Administration Public Data Open Project (openFDA).

  2025cites this paper
• Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database

  2025cites this paper
• Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox–Gastaut syndrome in clinical practice

  2024cites this paper
• What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice.

  2024cites this paper
• Fenfluramine in clinical practice: new therapy option for Dravet and Lennox–Gastaut syndromes

  2024cites this paper
• Innovative LC-MS/MS method for therapeutic drug monitoring of fenfluramine and cannabidiol in the plasma of pediatric patients with epilepsy.

  2024cites this paper
• Comprehensive scoping review of fenfluramine's role in managing generalized tonic–clonic seizures in developmental and epileptic encephalopathies

  2024cites this paper
• Dravet syndrome in adult population

  2024cites this paper
• New epilepsy therapies in development

  2024cites this paper
• Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real‐world study

  2024cites this paper
• Developmental and epileptic encephalopathies

  2024cites this paper
• Avances y orientaciones en el tratamiento de la epilepsia farmacorresistente: revisión de los nuevos fármacos cenobamato, fenfluramina y cannabidiol por la Sociedad Andaluza de Epilepsia

  2024cites this paper
• Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight

  2024influential citation
• A comprehensive review of evolving treatment strategies for Dravet syndrome: Insights from randomized trials, meta-analyses, real-world evidence, and emerging therapeutic approaches.

  2024cites this paper
• Fenfluramine treatment for Dravet syndrome: Long term real‐world analysis demonstrates safety and reduced health care burden

  2024cites this paper
• Recent advances in pharmacotherapy for epilepsy

  2023cites this paper
• Black-Box Warnings of Antiseizure Medications: What is Inside the Box?

  2023cites this paper
• Investigational new drugs for the treatment of Dravet syndrome: an update

  2023cites this paper
• Fenfluramine treatment for Dravet syndrome: Caregiver- and clinician-reported benefits on the quality of life of patients, caregivers, and families living in Germany, Spain, Italy, and the United Kingdom.

  2023cites this paper
• Dravet syndrome: A systematic literature review of the illness burden

  2023cites this paper
• Fenfluramine below the age of 2 years in Dravet syndrome: What about safety and efficacy?

  2023cites this paper
• Preocupaciones sobre la atención sanitaria en progenitores de niños con diferentes encefalopatías epilépticas genéticas del desarrollo: Un estudio cualitativo

  2023cites this paper
• Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies

  2023cites this paper
• Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo‐controlled clinical trial

  2023cites this paper
• Health care concerns in parents of children with different genetic developmental and epileptic encephalopathies: A qualitative study

  2023cites this paper
• Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes

  2023influential citation
• Dravet syndrome: Advances in etiology, clinical presentation, and treatment.

  2022cites this paper
• Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies

  2022cites this paper
• An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real‐world practice setting: A report from the Fenfluramine European Early Access Program

  2022cites this paper